II期临床研究-话题@MedSci

#II期临床研究#

109篇内容 | 2972人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1649994, encodeId=bea2164999492, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=35, createdTime=2019-10-07, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649991, encodeId=dda91649991da, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, objectType=article, longId=174985, objectId=0a901e49851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a901e49851b, replyNumber=0, likeNumber=69, createdTime=2019-11-09, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a901e49851b, moduleTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a901e49851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649995, encodeId=97c81649995f8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=88, createdTime=2020-01-22, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649988, encodeId=d45716499884e, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, objectType=article, longId=165928, objectId=8d7416592893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7416592893, replyNumber=0, likeNumber=102, createdTime=2019-12-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7416592893, moduleTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7416592893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650000, encodeId=132e165000021, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , objectType=article, longId=189573, objectId=89671895e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89671895e3b8, replyNumber=0, likeNumber=52, createdTime=2020-10-08, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89671895e3b8, moduleTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89671895e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649993, encodeId=f24e16499932e, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, objectType=article, longId=178786, objectId=cbc51e8786dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc51e8786dd, replyNumber=0, likeNumber=80, createdTime=2020-03-01, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc51e8786dd, moduleTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc51e8786dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649998, encodeId=aed316499984b, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, objectType=article, longId=182123, objectId=bacc18212334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacc18212334, replyNumber=0, likeNumber=68, createdTime=2020-02-08, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacc18212334, moduleTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacc18212334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649986, encodeId=5b0c164998621, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, objectType=article, longId=160563, objectId=3f571605635b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f571605635b, replyNumber=0, likeNumber=88, createdTime=2019-03-26, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f571605635b, moduleTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f571605635b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649999, encodeId=fc721649999a9, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=30, createdTime=2020-10-08, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649992, encodeId=add51649992d7, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=62, createdTime=2019-11-27, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649990, encodeId=f86d164999094, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, objectType=article, longId=174339, objectId=2db21e433919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db21e433919, replyNumber=0, likeNumber=77, createdTime=2019-07-11, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db21e433919, moduleTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db21e433919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649989, encodeId=d6c1164998991, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=罗沙司他全球III期临床研究证实其心血管安全性, objectType=article, longId=166305, objectId=121416630562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121416630562, replyNumber=0, likeNumber=106, createdTime=2020-03-01, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121416630562, moduleTitle=罗沙司他全球III期临床研究证实其心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121416630562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649987, encodeId=225d164998e05, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, objectType=article, longId=161507, objectId=c9f516150e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f516150e26, replyNumber=0, likeNumber=83, createdTime=2019-08-05, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f516150e26, moduleTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f516150e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649980, encodeId=e661164998035, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, objectType=article, longId=147648, objectId=0b0214e648e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b0214e648e1, replyNumber=0, likeNumber=74, createdTime=2019-03-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b0214e648e1, moduleTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b0214e648e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, objectType=article, longId=160427, objectId=61c716042e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c716042e5f, replyNumber=0, likeNumber=70, createdTime=2019-05-07, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c716042e5f, moduleTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c716042e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649982, encodeId=cd5f164998244, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=73, createdTime=2019-11-16, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649985, encodeId=943f1649985cc, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, objectType=article, longId=160548, objectId=fcad160548ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad160548ce, replyNumber=0, likeNumber=117, createdTime=2019-05-24, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad160548ce, moduleTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad160548ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649983, encodeId=1516164998333, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=0, createdTime=2019-05-12, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649981, encodeId=43d3164998165, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, objectType=article, longId=149146, objectId=06fb149146c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fb149146c6, replyNumber=0, likeNumber=64, createdTime=2019-07-14, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fb149146c6, moduleTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fb149146c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649978, encodeId=eaa416499e864, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, objectType=article, longId=130890, objectId=c161130890e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c161130890e4, replyNumber=0, likeNumber=70, createdTime=2018-12-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c161130890e4, moduleTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c161130890e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床研究

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-10-07

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ESMO世界胃肠癌大会：murlentamab的II期临床研究结果

2019-11-09

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2020-01-22

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

全球III期临床研究：roxadustat的心血管安全性得到证实

2019-12-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究

2020-10-08

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究

2020-03-01

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究

2020-02-08

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案

2019-03-26

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-10-08

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-11-27

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

斑蝥素治疗常见疣的II期临床研究取得积极成绩

2019-07-11

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

罗沙司他全球III期临床研究证实其心血管安全性

2020-03-01

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败

2019-08-05

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表

2019-03-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效

2019-05-07

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ALK阳性肺癌全新III期临床研究成果

2019-11-16

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究

2019-05-24

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-05-12

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景

2019-07-14

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究

2018-12-28

科室
- - 订阅+
  - 更多科室
工具
服务